pAMP Platform
Proprietary multi-epitope concatemeric peptide technology delivering broad immune coverage against complex pathogens.
Science
A patented concatemeric peptide platform for complex pathogens
The patented pAMP platform links many precisely defined immune targets into a single protein construct — broad coverage, straightforward manufacturing, no live virus.
pAMP Platform
Many targets, one construct
Conventional vaccines usually present the immune system with a single antigen. Complex and rapidly evolving pathogens can slip past that narrow view.
pAMP takes a different approach. Multiple carefully selected peptide epitopes — the specific fragments the immune system learns to recognize — are assembled into one repeating chain. The result is a construct that teaches both antibody and T-cell responses to recognize a pathogen from several angles at once.
Because the design is modular, epitopes can be swapped or extended as new strains emerge, without rebuilding the underlying platform.
Platform Technology
Programmable concatemer assembly, explained simply
The pAMP engineering method assembles short DNA fragments encoding selected peptide epitopes into a defined, repeating concatemeric sequence, which expression systems then produce as a single continuous protein construct — without any viral component or live pathogen.
STEP 01
Select the targets
Immunologically important peptide sequences are identified from the pathogen of interest — the regions most likely to drive protective immunity.
STEP 02
Assemble the DNA
Short DNA fragments encoding each target are joined into a defined, repeating order — a concatemer. The number and arrangement of units are controlled by design.
STEP 03
Express the construct
Standard recombinant expression systems produce the assembled peptide chain as a single protein product, using well-established bioprocessing methods.
STEP 04
Formulate for the field
The resulting construct is thermostable and non-replicating, enabling formulations that do not depend on continuous cold-chain infrastructure.
Platform Advantages
Designed for stockpiling, deployment, and scale
Programmable Concatemer Assembly
Enables precise, programmable assembly of repeating bioactive peptide units, producing non-replicating vaccine and therapeutic constructs with no viral vector or live pathogen.
Thermostable
Cold-chain independent formulation suitable for field deployment in resource-limited settings.
Scalable Manufacturing
Compatible with standard recombinant protein production — no live virus, no complex biologics infrastructure required.
Proven Versatility
Platform has demonstrated biological activity across multiple indications including infectious disease and wound healing applications.
Non-Replicating
No live or attenuated virus in the construct, supporting a favorable safety profile and streamlined biosafety handling.
Pipeline
One patented platform. Multiple programs.
The patented pAMP platform powers a multi-program pipeline spanning prophylactic vaccines and therapeutic candidates across high-consequence infectious diseases.
| Program | Pathogen | Indication | Stage | Funding Pathway |
|---|---|---|---|---|
| KNX-001 | Andes Virus (ANDV) | Hantavirus Pulmonary Syndrome (HPS) | Preclinical | Prophylactic Vaccine |
| KNX-002 | Rift Valley Fever Virus (RVFV) | Rift Valley Fever (RVF) | Preclinical | Prophylactic Vaccine |
| KNX-003 | RVFV & Hantavirus | Multi-Pathogen Viral Therapeutic | Discovery | Standalone Therapeutic |
| KNX-004 | RVFV & Hantavirus | Preventive / Therapeutic Combination Vaccine | Concept | Under Discussion |
Swipe the table horizontally to see all columns.
Interested in the platform?
We share technical detail and preclinical plans with government reviewers, scientific collaborators, and prospective partners under appropriate agreements.